A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries
AffiliationHarvard Kennedy School and School of Public Health, Boston, USA; Médecins Sans Frontières, Campaign for Access to Essential Medicines, Geneva, Switzerland
MetadataShow full item record
JournalGlobalization and Health
AbstractBackground: Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices systematically lower than in industrialized countries - has received widespread support from industry, policymakers, civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies, drug-resistant tuberculosis medicines, liposomal amphotericin B (for visceral leishmaniasis), and pneumococcal vaccines. Discussion: We found several critical shortcomings to tiered pricing: it is inferior to competition for achieving the lowest sustainable prices; it often involves arbitrary divisions between markets and/or countries, which can lead to very high prices for middle-income markets; and it leaves a disproportionate amount of decision-making power in the hands of sellers vis-à-vis consumers. In many developing countries, resources are often stretched so tight that affordability can only be approached by selling medicines at or near the cost of production. Policies that “de-link” the financing of R&D from the price of medicines merit further attention, since they can reward innovation while exploiting robust competition in production to generate the lowest sustainable prices. However, in special cases - such as when market volumes are very small or multi-source production capacity is lacking - tiered pricing may offer the only practical option to meet short-term needs for access to a product. In such cases, steps should be taken to ensure affordability and availability in the longer-term. Summary: To ensure access to medicines for populations in need, alternate strategies should be explored that harness the power of competition, avoid arbitrary market segmentation, and/or recognize government responsibilities. Competition should generally be the default option for achieving affordability, as it has proven superior to tiered pricing for reliably achieving the lowest sustainable prices.
- Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
- Authors: Plahte J
- Issue date: 2005 Jan
- Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
- Authors: Danzon PM, Towse A
- Issue date: 2003 Sep
- The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
- Authors: Babar ZU, Lessing C, Mace C, Bissell K
- Issue date: 2013 Nov
- [Risk sharing methods in middle income countries].
- Authors: Inotai A, Kaló Z
- Issue date: 2012
- Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
- Authors: Ooms G, Forman L, Williams OD, Hill PS
- Issue date: 2014 Dec 18